NSNurettin Suner

Nurettin Suner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nurettin Suner has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Kocataş

    Department of General Surgery, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, Director of Hospital, Istanbul, Turkey

    2 shared publications
  • Hasan Onal

    Department of Pediatrics, Başakşehir Çam and Sakura City Hospital, University of Health Sciences, İstanbul, Türkiye

    2 shared publications
  • Seda Yilmaz Semerci

    Department of Pediatrics, Division of Neonatology, Istinye University, Istanbul, Türkiye

    2 shared publications
  • Ali Kemal Kalkan

    Clinic of Cardiology, İstanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Türkiye

    1 shared publication
  • Bengu Arslan

    Department of Pediatric Nutrition and Metabolism Clinics, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, Istanbul, Turkey; Department of Pediatrics, Postdoctorate Fellow of Pediatric Nutrition and Metabolism, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

    1 shared publication
  • Bengü Arslan

    1 shared publication

Latest Publications

  • Open Access

    Angiotensin (1−7) peptide replacement therapy with plasma transfusion in COVID-19

    by Hasan Onal, Nurcan Ucuncu Ergun, Bengu Arslan, Seyma Topuz, Seda Yilmaz Semerci, Osman Mutluhan Ugurel, Murat Topuzogullari, Ali Kalkan, Sengul Aydin Yoldemir, Nurettin Suner, et al.


  • Open Access

    Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial

    by Hasan Önal, Bengü Arslan, Nurcan Üçüncü Ergun, Şeyma Topuz, Seda Yilmaz Semerci̇, Mehmet Eren Kurnaz, Yulet Miray Molu, Mehmet Abdussamet Bozkurt, Nurettin Süner, Ali Kocataş

    Scientific research continues on new preventive and therapeutic strategies against severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). So far, there is no proven curative treatment, and a valid alternative therapeutic approach needs to be developed. This study is designed to evaluate the effect of quercetin in COVID-19 treatment. This was a single-centre, prospective randomized controlled cohort study. Routine care versus QCB (quercetin, vitamin C, bromelain) supplementation was compared between 429 patients with at least one chronic disease and moderate-to-severe respiratory symptoms. Demographic features, signs, laboratory results and drug administration data of patients were recorded. The endpoint was that QCB supplementation was continued throughout the follow-up period from study baseline to discharge, intubation, or death. The most common complaints at the time of hospital admission were fatigue (62.4%), cough (61.1%), anorexia (57%), thirst (53.7%), respiratory distress (51%) and chills (48.3%). The decrease in CRP and ferritin levels was higher in the QCB group (all Ps were < 0.05). In the QCB group, the increase in platelet and lymphocyte counts was higher (all Ps were < 0.05). QCB did not reduce the risk of events during follow-up. Adjustments for statistically significant parameters, including the lung stage, use of favipiravir and presence of comorbidity did not change the results. While there was no difference between the groups in terms of event frequency, the QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. While there was no difference between the groups in terms of event frequency, QCB supplement group had more advanced pulmonar findings, and QCB supplement is shown to have a positive effect on laboratory recovery/results. Therefore, we conclude that further studies involving different doses and plasma level measurements are required to reveal the dose/response relationship and bioavailability of QCB for a better understanding of the role of QCB in the treatment of SARS CoV-2.